Mylan (MYL) and Pfizer's (PFE) Upjohn to Combine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/16/2026
- Wall Street rallies, Dow ends with record on US-Iran deal, oil price slide
- Fox to acquire Roku for $22 billion to create streaming and live content giant
- SpaceX extends gains premarket after biggest IPO ever values it at $2.1 trillion
- These 2 space stocks were upgraded at KeyBanc today
- Nvidia plans to raise at least $20 billion in bond sale
- Brixmor Property Group announces passing of former CEO James Taylor
- Wall Street rallies, Dow ends with record on US-Iran deal, oil price slide
- Wolfe Research sees substantial upside to AMD estimates
- This chip stock is seen as a key winner from SPCX "gravitational pull" effect
- Keenova Therapeutics to sell Percocet and Endocet businesses for $250 million
Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine
July 29, 2019 6:45 AM EDTHERTFORDSHIRE, England and PITTSBURGH and NEW YORK, July 29, 2019 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company. Pfizer shareholders would own 57% of the combined new company, and Mylan... More
